• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR Leads A$400 Million Financing Solution for Ampol

    7/12/26 6:34:00 PM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email

    KKR, a leading global investment firm, today announced its cornerstone investment in a A$400 million (US$275 million) financing solution (the "Financing") for Ampol Limited (ASX: ALD) ("Ampol"), anchored by KKR's private credit and insurance platforms. The investment will support Ampol’s refinancing initiatives and other general corporate purposes, in line with its Capital Allocation Framework.

    Listed on the ASX, Ampol operates an integrated fuel supply and marketing value chain in Australia that encompasses the Lytton refinery in Queensland, an extensive national network of terminals and pipelines, and a convenience retail footprint of approximately 1,700 sites. Ampol also maintains a significant presence in New Zealand with approximately 500 retail sites and has international operations via its trading and shipping capabilities based in Singapore and the USA.

    KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

    Diane Raposio, Partner and Head of Asia Credit and Markets, KKR, said, "We are focused on providing flexible capital to high-quality companies as they pursue their strategic objectives. Ampol is an established, strong investment-grade business with a long operating history and a sophisticated approach to capital management. We are pleased to partner with Ampol on this financing, building on KKR's track record in the ANZ region and across Asia Pacific."

    Greg Barnes, Group Chief Financial Officer, Ampol, said, "The transaction is another example of our proactive approach to funding and capital management. We are delighted with the significant support received from KKR on this occasion, and our collaboration with Temasek-backed Clifford Capital in arranging the transaction with our advisers. We have a meaningful presence in Singapore and value the partnership with KKR and Clifford Capital."

    KKR’s investment was supported by Clifford Capital, a Temasek-backed and Singapore-headquartered global infrastructure credit platform, reflecting the firm's capability in delivering tailored capital solutions and connecting institutional investors with leading corporates across the Asia Pacific region.

    Vidyasagar Pulavarti, Chief Investment Officer, Asset Management, Clifford Capital, said, "Private investment grade credit continues to present compelling opportunities for institutional investors seeking resilient, long-term returns. We are delighted to collaborate with KKR, Ampol and Barrenjoey on this transaction, which underscores Clifford Capital Asset Management’s role as a trusted partner in accessing, structuring and delivering high-quality private credit assets, underpinned by rigorous investment discipline and robust Investment Committee oversight through our Private Investment Grade strategy."

    KKR is making this investment from its Asia Pacific Credit strategy and insurance platform. In Australia, KKR has provided bespoke solutions to Family Doctor, a leading group of general practitioner clinics, DBG Health, a leading pharmaceutical company, and Lendi, a leading fintech, and financings to companies and sponsors across a range of industries and private credit strategies. Since 2019, KKR has committed more than US$9.1 billion across 63 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than US$28.4 billion.

    Disclaimer

    This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for the Financing in the United States or any other jurisdiction where to do so would be unlawful. The Company has not registered, and does not intend to register, any portion of the Financing in the United States or any other jurisdiction and does not intend to conduct a public offering of securities in any of these jurisdictions.

    In particular, the Financing has not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States. The Financing may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws. The offering is being made only to (a) persons outside of the United States or (b) "qualified institutional buyers" ("QIBs") within the meaning of Rule 144A under the Securities Act ("Rule 144A"). Prospective purchasers are hereby notified that the sellers or issuer of the Financing may be relying on the exemption from registration requirements of the Securities Act provided by Rule 144A or another available exemption from registration.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260708676320/en/

    Media Contacts



    For KKR:



    Wei Jun Ong

    +65 6922 5813

    WeiJun.Ong@kkr.com



    James Jarman

    +65 8870 6452

    James.Jarman@kkr.com

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    SEC Filings

    View All

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/29/26 4:16:25 PM ET
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/28/26 4:15:25 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form S-3ASR filed by KKR & Co. Inc.

    S-3ASR - KKR & Co. Inc. (0001404912) (Filer)

    5/11/26 5:06:43 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Alternative Assets Llc acquired $2,422,339 worth of Class I Common Stock (105,871 units at $22.88) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    7/2/26 4:05:37 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,523,312 worth of Class I Common Stock (65,491 units at $23.26) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    6/2/26 4:05:53 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,476,681 worth of Class I Common Stock (63,459 units at $23.27) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    5/4/26 4:05:48 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    Thomson Reuters and KKR Announce Joint Venture for Thomson Reuters Global Print Business

    TORONTO and NEW YORK, July 14, 2026 /CNW/ -- Thomson Reuters Corporation (TSX/Nasdaq: TRI) today announced that it has signed a definitive agreement to enter into a joint venture with KKR, a leading global investment firm. As part of the transaction, Thomson Reuters will sell a 51% stake in its Global Print business to capital accounts advised by KKR. Thomson Reuters will receive approximately $500 million in gross proceeds at closing and will retain a 49% equity interest in the joint venture. Thomson Reuters will also maintain intellectual property rights and full editorial control over its content portfolio. This new joint venture will hold an exclusive license to distribute the content in

    7/14/26 7:00:00 AM ET
    $TRI
    $KKR
    Publishing
    Consumer Discretionary
    Investment Managers
    Finance

    Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

    Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt

    7/14/26 6:02:00 AM ET
    $SPRO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Launches Allyntra, an Engineered Solutions Platform for Medical Technology and Precision Industries

    Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion. This press release feature

    7/9/26 6:59:00 AM ET
    $KKR
    $PRM
    Investment Managers
    Finance
    Major Chemicals
    Industrials

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

    PHILADELPHIA and NEW YORK, July 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its second quarter 2026 results before the opening of trading on the New York Stock Exchange on Thursday, August 6, 2026. FSK will host its second quarter 2026 results conference call via live webcast on Thursday, August 6, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the foll

    7/9/26 4:20:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. to Announce Second Quarter 2026 Results

    KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the second quarter 2026 on Thursday, July 30, 2026, before the opening of trading on the New York Stock Exchange.A conference call to discuss KKR’s financial results will be held on Thursday, July 30, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be avail

    7/1/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance